IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v27y2009i12p991-1004.html
   My bibliography  Save this article

Cost Effectiveness of Herpes Zoster Vaccine in Canada

Author

Listed:
  • Mehdi Najafzadeh
  • Carlo Marra
  • Eleni Galanis
  • David Patrick

Abstract

Background: Herpes zoster (HZ), or shingles, results from reactivation of latent varicella zoster virus in the sensory ganglia of adults, and results in significant morbidity in the elderly, including the development of postherpetic neuralgia (PHN). The lifetime risk of HZ is about 20–30% and the incidence increases with age. The protective effect of the HZ vaccine has been shown in a large clinical trial; however, the effectiveness of the vaccine decreased with age of vaccination. Objective: We sought to compare the incremental cost and health benefits of HZ vaccine over status quo (no HZ vaccine) from the perspective of the Canadian healthcare payer. Methods: We developed a discrete-event simulation model comparing the costs and QALYs accrued to patients receiving HZ vaccine to those who did not. The effect of the vaccine on the (i) incidence of severe, moderate or mild HZ; (ii) severity and duration of HZ; (iii) incidence of PHN among patients with HZ; (iv) duration of PHN; and (v) costs associated with treating HZ and PHN were modelled. Data from published literature, including the Shingle Prevention Study, were used for transition probabilities. Health resource utilizations were estimated using administrative data retrieved from the British Columbia Medical Services Plan and hospital separation databases in British Columbia from 1994 to 2003. Utility estimates were obtained from various published sources. Canadian 2008 costs were used and both cost and QALYs were discounted at a 5% annual rate in the base-case analyses. Results: On average, receiving the vaccination lowered mean direct medical costs (excluding the vaccine costs) by $Can35 per person. The incremental cost and QALYs per person receiving the vaccine versus no vaccination were $Can115 and 0.0028 QALYs, respectively, resulting in an incremental cost-effectiveness ratio of $Can41 709 per QALY gained for a cohort of elderly subjects aged ≥60 years. Results were robust in probabilistic and univariate sensitivity analyses. Expected value of perfect information was estimated at $Can47.72 per person, reflecting the expected monetary losses that could be avoided by having perfect information on all model parameters. Conclusion: HZ vaccination of adults, especially for individuals aged 60–75 years, seems to be a cost-effective intervention and might be considered by Canadian decision makers. Copyright Adis Data Information BV 2009

Suggested Citation

  • Mehdi Najafzadeh & Carlo Marra & Eleni Galanis & David Patrick, 2009. "Cost Effectiveness of Herpes Zoster Vaccine in Canada," PharmacoEconomics, Springer, vol. 27(12), pages 991-1004, December.
    • Handle: RePEc:spr:pharme:v:27:y:2009:i:12:p:991-1004
    DOI: 10.2165/11314010-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11314010-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11314010-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Alan Brennan & Samer Kharroubi & Anthony O'Hagan & Jim Chilcott, 2007. "Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms," Medical Decision Making, , vol. 27(4), pages 448-470, July.
    2. Elkan F. Halpern & Milton C. Weinstein & Maria G.M. Hunink & G. Scott Gazelle, 2000. "Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of Patients," Medical Decision Making, , vol. 20(3), pages 314-322, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Joke Bilcke & Frederik Verelst & Philippe Beutels, 2018. "Sponsorship Bias in Base-Case Values and Uncertainty Bounds of Health Economic Evaluations? A Systematic Review of Herpes Zoster Vaccination," Medical Decision Making, , vol. 38(6), pages 730-745, August.
    2. Jesús Isaac Vázquez-Serrano & Rodrigo E. Peimbert-García & Leopoldo Eduardo Cárdenas-Barrón, 2021. "Discrete-Event Simulation Modeling in Healthcare: A Comprehensive Review," IJERPH, MDPI, vol. 18(22), pages 1-20, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Montserrat Vera-Llonch & Ellen Dukes & Javier Rejas & Oleg Sofrygin & Marko Mychaskiw & Gerry Oster, 2010. "Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 35-44, February.
    2. Elizabeth G Bond & Lusine Abrahamyan & Mohammad K A Khan & Andrea Gershon & Murray Krahn & Ping Li & Rajibul Mian & Nicholas Mitsakakis & Mohsen Sadatsafavi & Teresa To & Petros Pechlivanoglou & for t, 2020. "Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-16, August.
    3. Wei Fang & Zhenru Wang & Michael B. Giles & Chris H. Jackson & Nicky J. Welton & Christophe Andrieu & Howard Thom, 2022. "Multilevel and Quasi Monte Carlo Methods for the Calculation of the Expected Value of Partial Perfect Information," Medical Decision Making, , vol. 42(2), pages 168-181, February.
    4. Niklas Zethraeus & Magnus Johannesson & Bengt Jönsson & Mickael Löthgren & Magnus Tambour, 2003. "Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 21(1), pages 39-48, January.
    5. Yunpeng Sun & Daniel W. Apley & Jeremy Staum, 2011. "Efficient Nested Simulation for Estimating the Variance of a Conditional Expectation," Operations Research, INFORMS, vol. 59(4), pages 998-1007, August.
    6. Oakley, Jeremy E. & Brennan, Alan & Tappenden, Paul & Chilcott, Jim, 2010. "Simulation sample sizes for Monte Carlo partial EVPI calculations," Journal of Health Economics, Elsevier, vol. 29(3), pages 468-477, May.
    7. Laura McCullagh & Cathal Walsh & Michael Barry, 2012. "Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting," PharmacoEconomics, Springer, vol. 30(10), pages 941-959, October.
    8. Sankararaman, S. & Mahadevan, S., 2013. "Separating the contributions of variability and parameter uncertainty in probability distributions," Reliability Engineering and System Safety, Elsevier, vol. 112(C), pages 187-199.
    9. Vinaytosh Mishra & Mohita G. Sharma, 2020. "Understanding Humanitarian Supply Chain Through Causal Modelling," South Asian Journal of Business and Management Cases, , vol. 9(3), pages 317-329, December.
    10. Sarazin, Gabriel & Morio, Jérôme & Lagnoux, Agnès & Balesdent, Mathieu & Brevault, Loïc, 2021. "Reliability-oriented sensitivity analysis in presence of data-driven epistemic uncertainty," Reliability Engineering and System Safety, Elsevier, vol. 215(C).
    11. Sankararaman, Shankar & Mahadevan, Sankaran, 2011. "Likelihood-based representation of epistemic uncertainty due to sparse point data and/or interval data," Reliability Engineering and System Safety, Elsevier, vol. 96(7), pages 814-824.
    12. Sandra Tunis & Luc Sauriol & Michael Minshall, 2010. "Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada," Applied Health Economics and Health Policy, Springer, vol. 8(4), pages 267-280, July.
    13. Susan Griffin & Nicky J. Welton & Karl Claxton, 2010. "Exploring the Research Decision Space: The Expected Value of Information for Sequential Research Designs," Medical Decision Making, , vol. 30(2), pages 155-162, March.
    14. Straub, Daniel & Ehre, Max & Papaioannou, Iason, 2022. "Decision-theoretic reliability sensitivity," Reliability Engineering and System Safety, Elsevier, vol. 221(C).
    15. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    16. Diana Beatriz Bayani & Yihao Clement Lin & Chandramouli Nagarajan & Melissa G. Ooi & Allison Ching Yee Tso & John Cairns & Hwee Lin Wee, 2024. "Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers," PharmacoEconomics - Open, Springer, vol. 8(5), pages 651-664, September.
    17. Cannon, Jeffrey W. & Mueller, Ute A. & Hornbuckle, Janet & Larson, Ann & Simmer, Karen & Newnham, John P. & Doherty, Dorota A., 2013. "Economic implications of poor access to antenatal care in rural and remote Western Australian Aboriginal communities: An individual sampling model of pregnancy," European Journal of Operational Research, Elsevier, vol. 226(2), pages 313-324.
    18. Neale Cohen & Michael Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William Valentine & Andrew Palmer, 2007. "Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin," PharmacoEconomics, Springer, vol. 25(10), pages 881-897, October.
    19. Sun-Young Kim & Sue Goldie, 2008. "Cost-Effectiveness Analyses of Vaccination Programmes," PharmacoEconomics, Springer, vol. 26(3), pages 191-215, March.
    20. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:27:y:2009:i:12:p:991-1004. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.